123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> Health >> View Article

Varicella Live Vaccine Market Statistics And Research Analysis Detailed In Latest Research Report

Profile Picture
By Author: EMRIndustry
Total Articles: 267
Comment this article
Facebook ShareTwitter ShareGoogle+ ShareTwitter Share

The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026.

Varicella live vaccines contain an attenuated form of the varicella zoster virus. These vaccines help build immunity against varicella zoster virus as the infection can cause serious diseases such as chicken pox and herpes zoster. Immunization against these diseases is necessary as chicken pox can lead to serious complications such as bacterial infections of the skin and soft tissues in children.

Moreover, herpes zoster is another painful condition that is caused by the reactivation of the varicella zoster virus after primary infection. Therefore, immunization with varicella live vaccine serves as an effective method for prevention of these diseases. These vaccines are mainly of two types such as monovalent and combination. The monovalent vaccines contain a single strain of a single antigen such as varicella live vaccines, contain weakened strain of varicella zoster virus. However, the combination varicella vaccines contain multiple strains ...
... of infectious agents.

The factors that boost the growth of the varicella live vaccine market include surge in immunization programs across the globe. Moreover, rise in awareness related to the use of varicella live vaccines and surge in adoption of varicella vaccination worldwide also fuel the growth of the varicella live vaccine market. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The global varicella live vaccine market is segmented based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization.

On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).


• This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

• By Product
o Monovalent Varicella Vaccine
o Combination Varicella Vaccine

• By Application
o Chickenpox immunization
o Herpes Zoster Immunization
o Mumps, Measles, Rubella and Varicella (MMRV) Immunization

• By Provider
o Public Provider
o Private Provider

• By Region
o North America
§ U.S.
§ Canada
§ Mexico

o Europe
§ Germany
§ France
§ UK
§ Italy
§ Spain
§ Rest of Europe

o Asia-Pacific
§ Japan
§ China
§ India
§ Australia
§ South Korea
§ Rest of Asia-Pacific

§ Brazil
§ Saudi Arabia
§ South Africa
§ Rest of LAMEA

List of key players profiled in the report:

• Bio-Med Pvt. Limited
• Changchun BCHT Biotechnology Co. Ltd.
• Emcure Pharmaceuticals Limited
• GlaxoSmithKline plc
• Green Cross Holdings (GC Pharma)
• Merck & Co. Inc.
• Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
• Novo Medi Sciences Pvt. Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• VHB Life Sciences
• Wockhardt Ltd.

Visit For More Information : Click Here

Total Views: 107Word Count: 594See All articles From Author

Add Comment

Health Articles

1. The Tale Of White Tea And Its Array Of Uses
Author: urmilakamble121

2. Buy Generic Cialis 40mg Online Uk | Tadalafil | Vidalista 40
Author: Pro Pharmacy Store

3. Minimally Invasive Spine And Pain Interventions (mipsi) Are Going To Be Game Changers In The Healthcare Industry
Author: Pankaj Surange

4. How To Naturally Lose Weight Fast ?
Author: Second Medic

5. Signs That You Need To Drink More Water
Author: Second Medic

6. Air Ambulance Cost From India To Usa
Author: Almas Ambulance

7. Revenue Benefits By Onboarding Dme Medical Billing Company
Author: Danny Johnsmith

8. Snus Shop Produkte Mit Weiteren Zusatzangeboten In Deutschland Und Österreich
Author: Snushuseu

9. Is It Safe To Whiten Your Teeth With Procedures?
Author: Akash Tiwari

10. Dental Implant- The Most Recommended Option For A Patient
Author: Social_blog

11. 7 Most Common Challenges With Oncology Billing
Author: Info Hub Team

12. Snus Online Produkte Mit Weiteren Zusatzangeboten
Author: Snushus

13. Back Pain Therapy Using Painkillers And Different Methods
Author: Daniel Paul

14. The Thin Spots: Where Hair Loss Concealers Work Best
Author: Kenny English

15. Mirna Sequencing And Assays Market Worth $ 343 Million By 2024 – Exclusive Report By Marketsandmarkets™
Author: Prachee

Login To Account
Login Email:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: